Results 71 to 80 of about 284,370 (314)

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study [PDF]

, 2018
BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 ...
Adiwijaya, Bambang S, Campbell, Karen, Geretti, Elena, Hendriks, Bart S, Krop, Ian E, LoRusso, Patricia, Ma, Cynthia, Miller, Kathy D, Molnár, István, Moyo, Victor, Munster, Pamela, Reynolds, Joseph, Shields, Anthony F, Siegel, Barry A, Wickham, Thomas J   +14 more
core   +2 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Ditsch, Nina, Friese, Klaus, Kahlert, Steffen, Kümper, Carolin, Lenhard, Miriam, Rückert, Sandra, Untch, Michael   +7 more
core   +2 more sources

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates [PDF]

Breast Cancer Research, 2020
Abstract Background There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). Methods Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug ...
Alberto Ocaña, Eitan Amir, Atanasio Pandiella   +2 more
openaire   +5 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

HER2 signaling regulates HER2 localization and membrane retention

PLOS ONE, 2017
ErbB2/HER2/Neu is a receptor tyrosine kinase that is overexpressed in 25-30% of human breast cancers, usually associated with amplification of the ERBB2 gene. HER2 has no recognized ligands and heterodimers between HER2 and EGFR (ErbB1/HER1) or HER2 and ErbB3/HER3 are important in breast cancer.
Jaekwang Jeong, Wonnam Kim, Lark Kyun Kim, Joshua VanHouten, John J Wysolmerski   +4 more
openaire   +5 more sources

HER2/positive and HER2/low in inflammatory breast cancer recurrence

Journal of Medicine and Life, 2022
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus.
Movchan, Oleksii Volodimirovich, Bagmut, Irina Yuriivna, Shipko, Andriy Fedorovich, Smolanka (Senior), Ivan Ivanovich, Sheremet, Michael Ivanovich, Kolisnyk, Igor Leonidovich, Bagmut, Oleksandr Vasyliovych, Lyashenko, Andriy Oleksandrovich, Loboda, Anton Dmitrovich, Ivankova, Oksana Mykolaivna, Dosenko, Irina Viktorivna, Lazaruk, Oleksandr Volodimirovich, Gyrla, Yan Viktorovich, Bilookyi, Oleksandr Vyacheslavovich   +13 more
openaire   +2 more sources

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

Breast Cancer: Targets and Therapy, 2023
Qianming Bai,1– 3,* Hong Lv,1– 3,* Longlong Bao,1– 3,* Yu Yang,1– 3 Xin Zhang,4 Heng Chang,1– 3 Tian Xue,1– 3 Min Ren,1– 3 Xiaoli Zhu,1– 3 Xiaoyan Zhou,1– 3,* Wentao Yang1– 3,* 1Department of Pathology, Fudan University Shanghai ...
Bai Q, Lv H, Bao L, Yang Y, Zhang X, Chang H, Xue T, Ren M, Zhu X, Zhou X, Yang W   +10 more
doaj  

Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]

, 2011
Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W., Blohmer, Jens-Uwe, Costa, Serban-Dan, Diedrich, Klaus, Diel, Ingo, Eiermann, Wolfgang, Friese, Klaus, Gerber, Bernd, Harbeck, Nadia, Hilfrich, Jörn, Jackisch, Christian, Janni, Wolfgang, Jonat, Walter, Jänicke, Fritz, Kaufmann, Manfred, Kiechle, Marion, Kreienberg, Rolf, Köhler, Uwe, Maass, Nicolai, Marschner, Norbert, Minckwitz, Gunter von, Möbus, Volker, Nitz, Ulrike, Scharl, Anton, Schneeweiss, Andreas, Thomssen, Christoph, Untch, Michael, Wallwiener, Diethelm   +27 more
core   +1 more source